MEDCO RES INC has a total of 27 patent applications. Its first patent ever was published in 1989. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are BENCHERIF MEROUANE, KING PHARMACEUTICALS RES & DEV and SANOFI AVENTIS US LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Australia | 4 | |
#3 | Canada | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Japan | 2 | |
#7 | China | 1 | |
#8 | Spain | 1 | |
#9 | United Kingdom | 1 | |
#10 | Israel | 1 | |
#11 | Romania | 1 | |
#12 | Yugoslavia (Serbia and Montenegro) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Analysing materials | |
#5 | Organic chemistry methods | |
#6 | Sugars | |
#7 | Diagnosis and surgery |
# | Name | Total Patents |
---|---|---|
#1 | Baraldi Pier Giovanni | 13 |
#2 | Borea Pier Andrea | 8 |
#3 | Hilleman Daniel E | 5 |
#4 | Mohiuddin Syed M | 5 |
#5 | Leung Edward | 4 |
#6 | Baraldi Pier G | 3 |
#7 | Garaldi Pier Giovanni | 1 |
Publication | Filing date | Title |
---|---|---|
AU5609700A | Use of adenosine to minimize reperfusion injury | |
AU5571299A | The use of adenosine A3 receptor antagonists to inhibit tumor growth | |
WO0010391A1 | The use of adenosine a3 receptor antagonists to inhibit tumor growth | |
US6323214B1 | Allosteric adenosine receptor modulators | |
AU8764398A | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators | |
US6048865A | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator | |
US5939432A | Thiophenes useful for modulating the adenosine receptor | |
JPH0347136A | Vascular diagnosticum | |
US5070877A | Novel method of myocardial imaging |